Smith Asset Management Group LP increased its stake in Repligen Corporation (NASDAQ:RGEN) by 2,577.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,739 shares of the biotechnology company’s stock after buying an additional 7,450 shares during the period. Smith Asset Management Group LP’s holdings in Repligen Corporation were worth $321,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. US Bancorp DE raised its position in Repligen Corporation by 1.2% in the second quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 54 shares during the last quarter. State of Alaska Department of Revenue raised its position in Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 80 shares during the last quarter. Arizona State Retirement System raised its position in Repligen Corporation by 0.6% in the second quarter. Arizona State Retirement System now owns 17,726 shares of the biotechnology company’s stock valued at $735,000 after buying an additional 100 shares during the last quarter. NBW Capital LLC raised its position in Repligen Corporation by 0.5% in the first quarter. NBW Capital LLC now owns 22,655 shares of the biotechnology company’s stock valued at $797,000 after buying an additional 118 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its position in Repligen Corporation by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 13,800 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 200 shares during the last quarter. 99.49% of the stock is owned by hedge funds and other institutional investors.

Repligen Corporation (NASDAQ:RGEN) opened at 41.61 on Tuesday. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of 81.43 and a beta of 1.30. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The company’s 50-day moving average price is $41.83 and its 200 day moving average price is $36.83.

Repligen Corporation (NASDAQ:RGEN) last released its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million during the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. Repligen Corporation’s revenue was up 11.0% compared to the same quarter last year. During the same period last year, the business posted $0.16 earnings per share. Analysts predict that Repligen Corporation will post $0.59 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Smith Asset Management Group LP Buys 7,450 Shares of Repligen Corporation (RGEN)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/15/smith-asset-management-group-lp-buys-7450-shares-of-repligen-corporation-rgen.html.

Several research analysts have recently commented on the company. Janney Montgomery Scott boosted their price target on Repligen Corporation from $42.00 to $47.00 in a research report on Friday, June 23rd. Zacks Investment Research lowered Repligen Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, June 6th. BidaskClub raised Repligen Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Jefferies Group LLC reissued a “hold” rating and issued a $40.00 price target (up from $33.00) on shares of Repligen Corporation in a research report on Wednesday, June 28th. Finally, William Blair assumed coverage on Repligen Corporation in a research report on Friday, July 21st. They issued an “outperform” rating for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $42.00.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.